How Amgen's CEO learned to listen--and why

Amgen ($AMGN) CEO Kevin Sharer tells McKinsey that he was "an awful listener"--not to mention arrogant--for years, until he cultivated the humility to stop "telling" 90% of the time and "move closer to 50-50." Otherwise, he says, he would miss important signals, particularly the ones that foretell danger. Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.